JP2020510000A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510000A5
JP2020510000A5 JP2019543833A JP2019543833A JP2020510000A5 JP 2020510000 A5 JP2020510000 A5 JP 2020510000A5 JP 2019543833 A JP2019543833 A JP 2019543833A JP 2019543833 A JP2019543833 A JP 2019543833A JP 2020510000 A5 JP2020510000 A5 JP 2020510000A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
phloroglucinol
formulation
oral dosage
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019543833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510000A (ja
JP7323451B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021505 external-priority patent/WO2018165404A1/en
Publication of JP2020510000A publication Critical patent/JP2020510000A/ja
Publication of JP2020510000A5 publication Critical patent/JP2020510000A5/ja
Priority to JP2023085724A priority Critical patent/JP2023116518A/ja
Application granted granted Critical
Publication of JP7323451B2 publication Critical patent/JP7323451B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019543833A 2017-03-08 2018-03-08 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤 Active JP7323451B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023085724A JP2023116518A (ja) 2017-03-08 2023-05-24 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468501P 2017-03-08 2017-03-08
US62/468,501 2017-03-08
PCT/US2018/021505 WO2018165404A1 (en) 2017-03-08 2018-03-08 Pharmaceutical formualtions of phloroglucinol and trimethylphloroglucinol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085724A Division JP2023116518A (ja) 2017-03-08 2023-05-24 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤

Publications (3)

Publication Number Publication Date
JP2020510000A JP2020510000A (ja) 2020-04-02
JP2020510000A5 true JP2020510000A5 (https=) 2021-04-15
JP7323451B2 JP7323451B2 (ja) 2023-08-08

Family

ID=61768496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543833A Active JP7323451B2 (ja) 2017-03-08 2018-03-08 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤
JP2023085724A Pending JP2023116518A (ja) 2017-03-08 2023-05-24 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023085724A Pending JP2023116518A (ja) 2017-03-08 2023-05-24 フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤

Country Status (11)

Country Link
US (2) US20200009076A1 (https=)
EP (1) EP3592337B1 (https=)
JP (2) JP7323451B2 (https=)
KR (1) KR102636273B1 (https=)
CN (1) CN110381925A (https=)
AU (1) AU2018231044B2 (https=)
CA (1) CA3053254C (https=)
DK (1) DK3592337T3 (https=)
EA (1) EA201992116A1 (https=)
ES (1) ES2958616T3 (https=)
WO (1) WO2018165404A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112535659B (zh) * 2019-09-20 2022-03-22 南京艾德凯腾生物医药有限责任公司 一种间苯三酚注射液的配制方法
KR102881504B1 (ko) 2019-12-20 2025-11-06 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
CN113750058B (zh) * 2020-06-01 2023-07-04 北京九能天远科技有限公司 一种间苯三酚冻干口崩片及其制备方法
AU2021292406B2 (en) * 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
KR20230058151A (ko) 2020-10-05 2023-05-02 엑스더블유파마 리미티드 감마-하이드록시부티르산 유도체의 변형된 방출 조성물
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN113304109A (zh) * 2021-06-08 2021-08-27 内蒙古大唐药业股份有限公司 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法
CN115282132B (zh) * 2022-02-10 2024-01-30 郑州大学第一附属医院 用于缓解ercp胆道痉挛的复合物及其制备方法
CN119325372A (zh) * 2022-06-13 2025-01-17 辛菲特罗制药有限公司 间苯三酚制剂和使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
JP4974419B2 (ja) 2001-06-12 2012-07-11 東和薬品株式会社 薬物含有徐放性顆粒およびそれを含む錠剤
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
ES2500316T3 (es) 2002-10-01 2014-09-30 Banner Pharmacaps, Inc. Composición entérica para la fabricación de una cubierta de cápsula blanda
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CA2696063C (en) 2007-08-15 2014-05-06 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing form
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US8524278B2 (en) 2009-02-13 2013-09-03 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
FR2984165B1 (fr) * 2011-12-16 2014-06-27 Pharmeuro Traitement des crises de migraines, notamment d'algies vasculaires de la face
MX365513B (es) 2013-03-15 2019-06-06 Aprecia Pharmaceuticals LLC Forma de dosificacion de dispersion rapida que contiene levetiracetam.
WO2014171542A1 (ja) 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
CN103494792B (zh) 2013-08-27 2015-03-04 寿光富康制药有限公司 一种复方间苯三酚冻干口腔崩解片及制备方法
KR101587142B1 (ko) * 2013-12-26 2016-01-21 한국유나이티드제약 주식회사 속방층과 2개의 서방층으로 이루어진 위장관 질환 치료용 모사프리드 구연산염 삼층정 서방제제
MX376083B (es) * 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
KR101758451B1 (ko) * 2015-06-10 2017-07-27 대화제약 주식회사 안정성이 개선된 플로로글루시놀 무수물 함유 속용성 정제의 제조방법

Similar Documents

Publication Publication Date Title
JP2020510000A5 (https=)
JP2016532655A5 (https=)
JP2019135264A5 (https=)
JP2012502015A5 (https=)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2017513836A5 (https=)
JP2010509374A5 (https=)
ES2600853T3 (es) Composición farmacéutica o nutracéutica gastrorresistente con resistencia contra la influencia de etanol
JP2008280351A5 (https=)
JP2009530398A5 (https=)
RS58911B1 (sr) Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
JP2014012726A5 (https=)
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP2013522219A5 (https=)
CN115697994A (zh) 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
JP2013531041A5 (https=)
JP2017531673A5 (https=)
JP2014505107A5 (https=)
JP2014505102A (ja) 多粒子ｌ−メントール製剤及びその関連する方法
JP2017508817A5 (https=)
Patel et al. Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system
HRP20220856T1 (hr) Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe
JP2013514979A5 (https=)
JP2017519028A5 (https=)
JP2009503045A5 (https=)